AGP Picks
View all

Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication

News originally published by

GlobeNewswire

Vancouver, Canada, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.

The patent application is part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.

The Hong Kong patent publication expands Clearmind's global patent application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application supports the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.

According to market research by Heimdall Insights, the global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to reach $24.8 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 5.5%. In addition, GlobalData projects that the PTSD pharmaceutical market across seven major markets is projected to grow from $1.2 billion in 2024 to $5.5 billion by 2034, at a CAGR of 16.1%,  reflecting anticipated demand for innovative treatment options.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of the novel compounds covered by the patent application; the Company's ability to develop, manufacture, and commercialize such compounds; the potential commercial opportunities associated with such compounds; the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across key global markets; and expected growth in the PTSD pharmaceutical market. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.



Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Georgian Technology News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.